World Courant
Bins of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Nice Britain, on March 8, 2024.
Hollie Adams | Reuters
European Union drug regulators discovered no proof that extremely in style weight reduction and diabetes medication corresponding to Wegovy and Ozempic are linked to an elevated threat of suicidal ideas and self-harm, the regulator stated on Friday.
The European Medicines Company spent 9 months investigating so-called GLP-1s, a category of profitable therapies that mimic a hormone produced within the intestine to suppress an individual’s urge for food. Demand for these medication has skyrocketed previously 12 months, regardless of their excessive worth tags and poor insurance coverage protection.
The evaluation examined a number of medicines Novo Nordisk, together with Wegovy and Ozempic. It did not embody Eli Lilly‘s Zepbound and Mounjaro, two variations of the identical drug bought for weight reduction and diabetes. However the probe did embody the energetic ingredient in an older diabetes remedy from Eli Lilly known as Trulicity.
Novo Nordisk didn’t instantly reply to a request for touch upon the EMA’s findings.
The company’s evaluation is the most recent in a collection of reassuring experiences on the suicide threat for GLP-1s. The US Meals and Drug Administration got here to an analogous resolution conclusion in January, however stated company officers couldn’t definitively rule out {that a} “small threat may exist.”
Scientific research from Novo Nordisk and Eli Lilly have proven no hyperlink between GLP-1s and suicidal ideation. Nonetheless, researchers and docs are searching for new undesirable uncomfortable side effects or extra dangers as hundreds of recent sufferers begin utilizing the medication.
The EMA first launched its investigation in July after the Icelandic Medicines Company famous three circumstances of suicidal ideas and self-harm in sufferers taking medicines containing liraglutide and semaglutide, the energetic substances within the in style therapies.
Semaglutide is the energetic ingredient used within the diabetes capsule Rybelsus from Wegovy, Ozempic and Novo Nordisk. Liraglutide is the energetic ingredient in Saxenda, Novo Nordisk’s older weight-loss drug. The probe additionally included different energetic substances in older weight reduction and diabetes medication, together with dulaglutide, exenatide and lixisenatide.
The EMA stated on Friday that it analyzed the outcomes of a giant US research and located no direct hyperlink between semaglutide use and suicidal ideas. Outcomes from one other research carried out by the company additionally didn’t assist a hyperlink between GLP-1 medicines and the chance of suicidal ideas.
Each research had been primarily based on digital medical data.
In case you are having suicidal ideas or are in misery, please contact the Suicide and disaster lifeline at 988 within the US or the Samaritans in Nice Britain on 116 123 for assist and help from a educated advisor.
Weight reduction, diabetes medicines not linked to suicidal ideation: EU research
World Information,Subsequent Large Factor in Public Knowledg
